<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302808</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012011-004</org_study_id>
    <secondary_id>CDR0000653093</secondary_id>
    <secondary_id>NCI-2011-01035</secondary_id>
    <secondary_id>STU 012011-004</secondary_id>
    <nct_id>NCT01302808</nct_id>
  </id_info>
  <brief_title>Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Study of Erlotinib and Romidepsin in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of romidepsin when&#xD;
      given together with erlotinib hydrochloride and to see how well they work in treating&#xD;
      patients with stage III or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To characterize the toxicity and determine the maximum-tolerated dose (MTD) of erlotinib&#xD;
           hydrochloride plus romidepsin. (Phase I)&#xD;
&#xD;
        -  To obtain preliminary data regarding efficacy, including response rate and&#xD;
           progression-free survival. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize the pharmacokinetic profile of romidepsin in combination with erlotinib&#xD;
           hydrochloride.&#xD;
&#xD;
        -  To evaluate the impact of erlotinib hydrochloride on the biologic activity of romidepsin&#xD;
           by analyzing peripheral blood mononuclear cell (PBMC) histone acetylation status and&#xD;
           histone acetylase activity. (Exploratory)&#xD;
&#xD;
        -  To evaluate the effect of romidepsin and erlotinib hydrochloride on components of the&#xD;
           EGFR (epidermal growth factor receptor)-signaling pathway in skin biopsies, particularly&#xD;
           downstream mediators such as MAPK (mitogen-activated protein kinase). (Exploratory)&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of romidepsin followed by a phase II study.&#xD;
&#xD;
      Patients receive romidepsin IV on days 1, 8, and 15 and erlotinib hydrochloride orally (PO)&#xD;
      once daily beginning on day 3 of course 1 and on days 1-28 of all subsequent courses. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection at baseline and periodically during study for&#xD;
      pharmacokinetic studies. Additional samples of peripheral blood mononuclear cells and skin&#xD;
      biopsies may be also collected for correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39 patients (15 patients for phase I and 24 patients for phase&#xD;
      II) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities and Maximum Tolerated Dose (MTD)</measure>
    <time_frame>12 months</time_frame>
    <description>Dose limiting toxicities per Protocol definition using (CTCAE), Version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC0 t) of Romidepsin in Combination With Erlotinib</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on Days 1 and 8</time_frame>
    <description>AUC0 t was measured in the time interval from 0 to time (t) when the last blood sample is collected with a concentration above the limit of quantification.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Erlotinib plus Romidepsin (8 mg/m^2)</intervention_name>
    <arm_group_label>Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))</arm_group_label>
    <other_name>Istodax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Erlotinib plus Romidepsin (10 mg/m^2)</intervention_name>
    <arm_group_label>Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))</arm_group_label>
    <other_name>Istodax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis</intervention_name>
    <arm_group_label>Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis</intervention_name>
    <arm_group_label>Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible for study participation, patients must fulfill all of the following&#xD;
        criteria:&#xD;
&#xD;
          -  Histologically confirmed locally advanced or metastatic (stage IIIB pleural effusion&#xD;
             or stage IV) NSCLC;&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST);&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group ) performance status 0 to 1;&#xD;
&#xD;
          -  Serum potassium and magnesium greater than or equal to the lower limit of&#xD;
             institutional normal range (electrolyte abnormalities may be corrected with&#xD;
             supplementation to meet inclusion criteria);&#xD;
&#xD;
          -  Negative urine or serum pregnancy test on females of childbearing potential;&#xD;
&#xD;
          -  All women of childbearing potential must use an effective barrier method of&#xD;
             contraception (an intrauterine contraceptive device [IUCD] or double barrier method&#xD;
             using condoms or a diaphragm plus spermicide) during the treatment period and for at&#xD;
             least 1 month thereafter. Male patients should use a barrier method of contraception&#xD;
             during the treatment period and for at least 1 month thereafter. Hormonal methods of&#xD;
             contraception such as the contraceptive pill or patch (particularly those containing&#xD;
             ethinyl-estradiol) should be avoided due to a potential drug interaction (see Appendix&#xD;
             D).&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal function as evidenced by&#xD;
&#xD;
          -  Hemoglobin ≥10 g/dL (transfusions and/or erythropoietin-stimulating agents are&#xD;
             permitted)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.5 x 109 cells/L • Platelet count ≥100 x 109 cells/L&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  (Aspartate amino transferase) AST/SGOT(serum glutamic-oxaloacetic transaminase) and&#xD;
             (amino alanine transferase) ALT/SGPT (serum glutamic-pyruvic transaminase) &lt;2.0 x&#xD;
             upper limit of normal (ULN) or &lt;3.0 x ULN in the presence of demonstrable liver&#xD;
             metastases&#xD;
&#xD;
          -  Serum creatinine &lt;2.0 x ULN&#xD;
&#xD;
          -  Clinically stable brain metastases are permitted&#xD;
&#xD;
        Phase I study:&#xD;
&#xD;
          -  Prior erlotinib therapy is permitted (with a 3-week washout period)&#xD;
&#xD;
          -  Patients may have received prior anti-cancer therapy (with a 3-week washout period)&#xD;
             or, at the discretion of the investigator, may be treatment-naïve&#xD;
&#xD;
        Phase II study:&#xD;
&#xD;
          -  Patients must have received at least one and no more than two prior chemotherapy&#xD;
             regimens for their advanced NSCLC&#xD;
&#xD;
          -  Patients may not have received prior erlotinib&#xD;
&#xD;
        Patients are ineligible for entry if any of the following criteria are met:&#xD;
&#xD;
          -  Chemotherapy for NSCLC within 3 weeks prior to study entry;&#xD;
&#xD;
          -  Concomitant use of any other anti-cancer therapy;&#xD;
&#xD;
          -  Concomitant use of any investigational agent;&#xD;
&#xD;
          -  Use of any investigational agent within 4 weeks prior to study entry;&#xD;
&#xD;
          -  Any known cardiac abnormalities such as:&#xD;
&#xD;
               -  Congenital long QT syndrome;&#xD;
&#xD;
               -  QTc interval (corrected QT interval) Myocardial infarction within 12 months prior&#xD;
                  to study entry;&#xD;
&#xD;
               -  Other significant ECG abnormalities including type II second-degree atrio&#xD;
                  ventricular (AV) block, third-degree AV block, or bradycardia (ventricular rate &lt;&#xD;
                  50 beats/min); o A history of coronary artery disease (CAD); eg, angina Canadian&#xD;
                  Class II-IV. In any patient in whom there is doubt, the patient should have a&#xD;
                  stress imaging study and, if abnormal, angiography to define whether or not CAD&#xD;
                  is present;&#xD;
&#xD;
               -  An ECG recorded at screening showing significant ST depression (ST depression of&#xD;
                  ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec from&#xD;
                  the end of the QRS complex). If there is any doubt, the patient should have a&#xD;
                  stress imaging study and, if abnormal, angiography to define whether or not CAD&#xD;
                  is present;&#xD;
&#xD;
               -  Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class&#xD;
                  II to IV definitions and/or ejection fraction &lt; 40% by MUGA ( multiple gated&#xD;
                  acquisition) scan or &lt;50% by echocardiogram and/or MRI;&#xD;
&#xD;
               -  A known history of sustained ventricular tachycardia (VT), ventricular&#xD;
                  fibrillation (VF), Torsades de Pointes, or cardiac arrest unless currently&#xD;
                  addressed with an automatic implantable cardiac defibrillator (AICD);&#xD;
&#xD;
               -  Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or&#xD;
                  other causes (if there is any doubt, see ejection fraction criteria above);&#xD;
&#xD;
               -  Uncontrolled hypertension (defined as blood pressure [BP] ≥160/95; or&#xD;
&#xD;
               -  Any cardiac arrhythmia requiring anti-arrhythmic medication;&#xD;
&#xD;
          -  Serum potassium or serum magnesium below lower limit of institutional normal range&#xD;
             (electrolyte abnormalities may be corrected with supplementation to meet inclusion&#xD;
             criteria)&#xD;
&#xD;
          -  Concomitant use of drugs that may cause a prolongation of the QTc interval .&#xD;
&#xD;
          -  Concomitant use of CYP3A4 inhibitors&#xD;
&#xD;
          -  Concomitant use of warfarin (due to a potential drug interaction);&#xD;
&#xD;
          -  Clinically significant active infection (including known infection with human&#xD;
             immunodeficiency virus [HIV], hepatitis B, or hepatitis C); l &gt;480 milliseconds&#xD;
             (msec);&#xD;
&#xD;
          -  Major surgery or radiation within 2 weeks prior to study entry;&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding;&#xD;
&#xD;
          -  Any significant medical or psychiatric condition that might prevent the patient from&#xD;
             complying with all study procedures;&#xD;
&#xD;
          -  Prior exposure to romidepsin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E. Gerber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 19, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>David E Gerber</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage III B non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>malignant pleural effusion</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (Erlotinib Plus Romidepsin (8 mg/m^2))</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 (Erlotinib Plus Romidepsin (10 mg/m^2))</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 (Erlotinib Plus Romidepsin (10 mg/m^2)) + Antiemetic Prophylaxis</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4 (Erlotinib Plus Romidepsin (8 mg/m^2)) + Antiemetic Prophylaxis</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 (Erlotinib Plus Romidepsin (8 mg/m^2))</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 (Erlotinib Plus Romidepsin (10 mg/m^2))</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 (Erlotinib Plus Romidepsin (10 mg/m^2)) + Antiemetic Prophylaxis</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4 (Erlotinib Plus Romidepsin (8 mg/m^2)) + Antiemetic Prophylaxis</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities and Maximum Tolerated Dose (MTD)</title>
        <description>Dose limiting toxicities per Protocol definition using (CTCAE), Version 3.0</description>
        <time_frame>12 months</time_frame>
        <population>Only phase 1 data are reported here as the phase 2 component of the study was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Erlotinib Plus Romidepsin (8 mg/m^2))</title>
            <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (Erlotinib Plus Romidepsin (10 mg/m^2))</title>
            <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (Erlotinib Plus Romidepsin (10 mg/m^2)) + Antiemetic Prophylaxis</title>
            <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 (Erlotinib Plus Romidepsin (8 mg/m^2)) + Antiemetic Prophylaxis</title>
            <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities and Maximum Tolerated Dose (MTD)</title>
          <description>Dose limiting toxicities per Protocol definition using (CTCAE), Version 3.0</description>
          <population>Only phase 1 data are reported here as the phase 2 component of the study was not performed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Maximum Tolerated Dose</param_type>
            <param_value>8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve (AUC0 t) of Romidepsin in Combination With Erlotinib</title>
        <description>AUC0 t was measured in the time interval from 0 to time (t) when the last blood sample is collected with a concentration above the limit of quantification.</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on Days 1 and 8</time_frame>
        <population>After exhausting all means to obtain the data, we were only able to find data per dosage and not by cohort. Pharmacokinetic profile will not be affected by antiemetic prophylactic drug and therefore data were reported per dose.&#xD;
Only phase 1 data are reported here as the phase 2 component of the study was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Plus Romidepsin Cohort 1 (8mg/m2) + Cohort 4 (Modified Prophylaxis @ 8 mg/m2)</title>
            <description>Erlotinib 150 mg orally daily plus romidepsin IV days 1, 8, 15 (dose escalated) every 28 days&#xD;
erlotinib&#xD;
romidepsin</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (10mg/m2) +Cohort 3 ( Modified Prophylaxis @ 10 mg/m2)</title>
            <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle (cohort 2), with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle (cohort 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC0 t) of Romidepsin in Combination With Erlotinib</title>
          <description>AUC0 t was measured in the time interval from 0 to time (t) when the last blood sample is collected with a concentration above the limit of quantification.</description>
          <population>After exhausting all means to obtain the data, we were only able to find data per dosage and not by cohort. Pharmacokinetic profile will not be affected by antiemetic prophylactic drug and therefore data were reported per dose.&#xD;
Only phase 1 data are reported here as the phase 2 component of the study was not performed.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dosing day / Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1207.00" spread="529.01"/>
                    <measurement group_id="O2" value="2185.52" spread="717.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosing day / Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="989.19" spread="244.65"/>
                    <measurement group_id="O2" value="1851.84" spread="726.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 (Erlotinib Plus Romidepsin (8 mg/m^2))</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 (Erlotinib Plus Romidepsin (10 mg/m^2))</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 (Erlotinib Plus Romidepsin (10 mg/m^2)) + Antiemetic Prophylaxis</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4 (Erlotinib Plus Romidepsin (8 mg/m^2)) + Antiemetic Prophylaxis</title>
          <description>Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only phase 1 data are reported here as the maximum tolerated dose of romidepsin in combination with standard erlotinib 150 mg orally daily administration was 8 mg/m2. Therefore, it did not proceed to phase 2 (14 mg/m2 )</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Gerber, MD</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>2146484180</phone>
      <email>david.gerber@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

